These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26752166)

  • 21. Impact of therapy on the outcome of chronic hepatitis B.
    Liaw YF
    Liver Int; 2013 Feb; 33 Suppl 1():111-5. PubMed ID: 23286854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
    Buti M
    Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current developments in nucleoside/nucleotide analogues for hepatitis B.
    Lo AO; Wong GL
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):607-22. PubMed ID: 24787673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of HBsAg quantification for monitoring natural history and treatment outcome.
    Martinot-Peignoux M; Lapalus M; Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():125-32. PubMed ID: 23286856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
    Fung J; Lai CL; Yuen MF
    Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monotherapy versus combination therapy for the treatment of chronic hepatitis B.
    Carey I; Harrison PM
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1655-66. PubMed ID: 19852566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current issues and future directions in treatment.
    Hui CK; Lau GK
    Semin Liver Dis; 2006 May; 26(2):192-7. PubMed ID: 16673297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural course of chronic hepatitis B virus infection and its management.
    Hadziyannis SJ; Vassilopoulos D; Hadziyannis E
    Adv Pharmacol; 2013; 67():247-91. PubMed ID: 23886003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New advances in chronic hepatitis B.
    Tujios SR; Lee WM
    Curr Opin Gastroenterol; 2012 May; 28(3):193-7. PubMed ID: 22450894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression.
    Price N; Boxall EH
    J Antimicrob Chemother; 2007 Dec; 60(6):1189-92. PubMed ID: 17913721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.